Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–78—In this Article, the percentage of participants with antibodies detectable at a lower level has been corrected to 18% in the last paragraph of the Results. Additionally, the appendix has been corrected. These corrections have been made to the online version as of Aug 13, 2020, and the printed version is correct.
. 2020 Aug 13;396(10249):466. doi: 10.1016/S0140-6736(20)31687-1
Department of Error
Issue date 2020 15-21 August.
© 2020 The Author(s). Published by Elsevier Ltd.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC7426077 PMID: 32798485
This corrects the article "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial" on page 467.